Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Expansion Continues, with Forecast Valuation of $8.12 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for lateral flow immunoassay (lfia) based rapid test has seen a significant drop in the past few years. It is forecasted to decrease further from $8.03 billion in 2024 to $7.17 billion in 2025, exhibiting a negative compound annual growth rate (CAGR) of -10.7%. The reduction during the historical period can be ascribed to factors such as inadequate sensitivity and specificity, the intricacies involved in multiplexing, issues with cross-reactivity, constraints with storage and shelf-life, and limited capabilities for quantitative analysis.

Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Size Forecast: What's the Projected Valuation by 2029?
The market for the rapid test based on the lateral flow immunoassay (lfia) is projected to experience consistent growth in the upcoming years. The market size is estimated to reach $8.12 billion in 2029, with a compound annual growth rate (CAGR) of 3.2%. Factors such as global supply chain interruptions, regulatory issues, burgeoning competition, the rise of alternative technologies, and integration with digital health platforms could potentially cause a decrease during the forecast period. Within this period, notable trends would involve the creation of advanced technologies for multiple or repetitive LFIA based rapid tests, the emphasis on partnerships and collaborations, development of home testing kits, the investment in artificial intelligence-driven tests for disease diagnosis and detection, and the initiative to create low-cost testing kits for affordable patient access.

View the full report here:
https://www.thebusinessresearchcompany.com/report/lateral-flow-immunoassay-based-rapid-test-global-market-report

What Are the Drivers Transforming the Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
Continuous quality assurance continues to present a major hurdle to the growth of the rapid test market based on lateral flow immunoassay (LFIA). Factors such as rising operational expenses, inclusive of employee pay and investment in technology, are putting a strain on numerous law firms' profitability. For example, PLOS, a non-profit organization based in the US, reported in June 2023 that LFIA products available in the market do not always uphold stringent standards of reliability and specificity. A backward analysis of four LFIA tests showed considerable variation in their diagnostic accuracy, with a few tests displaying just 47% accuracy in IgG detection.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3293&type=smp

What Long-Term Trends Will Define the Future of the Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
Leading organizations functioning in the lateral flow immunoassay (LFIA)-based rapid test market are turning to techniques such as qPCR technology to optimize the precision and sensitivity of their tests, quicken the detection process, and broaden the spectrum of pathogens or biomarkers that can be distinguished. This strategy is geared towards developing more trustworthy and precise diagnostic tools for a variety of healthcare uses. QPCR (quantitative polymerase chain reaction) technology, a method used in molecular biology, amplifies and measures DNA or RNA sequences in real-time. This method provides accurate assessment of gene expression levels or the identification of specific pathogens in different samples. For instance, in November 2023, F. Hoffmann-La Roche AG, a pharmaceutical firm based in Switzerland, introduced the LightCycler PRO System. Building on Roche's previous qPCR systems, the LightCycler PRO employs the gold-standard technology for superior quality, precision, and dependability. These qualities are of utmost importance for exact patient diagnosis and informed clinical decision-making.

Which Segments in the Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Offer the Most Profit Potential?
The lateral flow immunoassay (lfia) based rapid test market covered in this report is segmented -

1) By Technique: Competitive Assay, Sandwich Assay, Multiplex Detection Assay
2) By Application: Infectious Disease, Pregnancy And Fertility, Toxicology, Cardiac Marker And Cholesterol Testing, Other Applications
3) By End-Users: Hospitals And Clinics, Diagnostic Laboratories, Home Care, Other End Users

Subsegments:
1) By Competitive Assay: Direct Competitive Assays, Indirect Competitive Assays
2) By Sandwich Assay: Single-step Sandwich Assays, Two-step Sandwich Assays
3) By Multiplex Detection Assay: Multi-analyte Assays, Simultaneous Detection Of Various Targets

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3293&type=smp

Which Firms Dominate the Lateral Flow Immunoassay (LFIA) Based Rapid Test Market by Market Share and Revenue in 2025?
Major companies operating in the lateral flow immunoassay (LFIA) based rapid test market include Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton, Dickinson and Company, Danaher Corporation, Siemens AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hologic, Inc., LTEK Co., Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, Charles River Laboratories, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd, Qiagen N.V., Merck KGaA, XPhyto Therapeutics, 3a Diagnostics, Roche Holding AG, BATM, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, CTK Biotech

Which Regions Offer the Highest Growth Potential in the Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2024. Asia-Pacific was the second largest region in the global lateral flow immunoassay (LFIA) based rapid test market. The regions covered in the lateral flow immunoassay (LFIA) based rapid test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3293

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.